Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 21 Apr 2010 |
| Genmab Announces Pipeline and Technology Update | 21 Apr 2010 |
| Passing of Genmab A/S' Annual General Meeting | 21 Apr 2010 |
| Constitution of the Board of Directors in Genmab and Grant of Warrants to Employees | 21 Apr 2010 |
| GlaxoSmithKline Receives Conditional Marketing Authorization in the EU for Arzerra™ (ofatumumab) | 19 Apr 2010 |